NeoGenomics (NEO) announced that Tony Zook has officially assumed the role of CEO. A member of the company’s board of directors since 2023, Zook brings more than three decades of experience across diagnostics and biopharma. Zook succeeds Chris Smith, who will continue in an advisory role to support a seamless transition.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics Promotes Warren Stone to President & COO
- NeoGenomics COO Melody Harris to depart, Warren Stone to succeed
- Strategic Acquisition of Pathline Boosts NeoGenomics’ Market Presence and Testing Capabilities
- NeoGenomics’ Strategic Acquisition of Pathline: A Low-Risk Investment for Market Expansion and Growth
- NeoGenomics acquires Pathline, terms undisclosed